Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.

BioNTech stock was rising after the drugmaker reported better-than-expected results early Monday. The company’s ...